JCI Insight (Apr 2022)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

  • Virginia Laspidea,
  • Montserrat Puigdelloses,
  • Sara Labiano,
  • Lucía Marrodán,
  • Marc Garcia-Moure,
  • Marta Zalacain,
  • Marisol Gonzalez-Huarriz,
  • Naiara Martínez-Vélez,
  • Iker Ausejo-Mauleon,
  • Daniel de la Nava,
  • Guillermo Herrador-Cañete,
  • Javier Marco-Sanz,
  • Elisabeth Guruceaga,
  • Carlos E. de Andrea,
  • María Villalba,
  • Oren Becher,
  • Massimo Squatrito,
  • Verónica Matía,
  • Jaime Gállego Pérez-Larraya,
  • Ana Patiño-García,
  • Sumit Gupta,
  • Candelaria Gomez-Manzano,
  • Juan Fueyo,
  • Marta M. Alonso

Journal volume & issue
Vol. 7, no. 7

Abstract

Read online

Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors, and patient survival has not changed despite many therapeutic efforts, emphasizing the urgent need for effective treatments. Here, we evaluated the anti-DIPG effect of the oncolytic adenovirus Delta-24-ACT, which was engineered to express the costimulatory ligand 4-1BBL to potentiate the antitumor immune response of the virus. Delta-24-ACT induced the expression of functional 4-1BBL on the membranes of infected DIPG cells, which enhanced the costimulation of CD8+ T lymphocytes. In vivo, Delta-24-ACT treatment of murine DIPG orthotopic tumors significantly improved the survival of treated mice, leading to long-term survivors that developed immunological memory against these tumors. In addition, Delta-24-ACT was safe and caused no local or systemic toxicity. Mechanistic studies showed that Delta-24-ACT modulated the tumor-immune content, not only increasing the number, but also improving the functionality of immune cells. All of these data highlight the safety and potential therapeutic benefit of Delta-24-ACT the treatment of patients with DIPG.

Keywords